Lukáš Ondrák, Kateřina Ondrák Fialová, Michal Sakmár, Martin Vlk, Frank Bruchertseifer, Alfred Morgenstern, Ján Kozempel
BACKGROUND: Radioligand therapy using alpha emitters has gained more and more prominence in the last decade. Despite continued efforts to identify new appropriate radionuclides, the combination of 225 Ac/213 Bi remains among the most promising. Bismuth-213 has been employed in clinical trials in combination with appropriate vectors to treat patients with various forms of cancer, such as leukaemia, bladder cancer, neuroendocrine tumours, melanomas, gliomas, or lymphomas. However, the half-life of 213 Bi (T½ = 46 min) implies that its availability for clinical use is limited to hospitals possessing a 225 Ac/213 Bi radionuclide generator, which is still predominantly scarce...
March 28, 2024: Nuclear Medicine and Biology